[HTML][HTML] FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
Patients with FLT3-mutated AML have a high relapse rate and suboptimal outcomes. Many
have co-mutations suitable for measurable residual disease (MRD) monitoring by RT-qPCR …
have co-mutations suitable for measurable residual disease (MRD) monitoring by RT-qPCR …
Evaluation of the detection of GBA missense mutations and other variants using the Oxford Nanopore MinION
…, M Toffoli, S Mullin, K Mokretar… - Molecular genetics & …, 2019 - Wiley Online Library
… To investigate false-positive SNVs further, we reviewed k-mer motifs which were prone to
error according to NanoOK for the commonest false positive (chr1: 155,211,111A>G, found in …
error according to NanoOK for the commonest false positive (chr1: 155,211,111A>G, found in …
Somatic copy number gains of α-synuclein (SNCA) in Parkinson's disease and multiple system atrophy brains
K Mokretar, D Pease, JW Taanman, A Soenmez, A Ejaz… - Brain, 2018 - academic.oup.com
The α-synuclein protein, encoded by SNCA, has a key role in the pathogenesis of Parkinson’s
disease and other synucleinopathies. Although usually sporadic, Parkinson’s disease can …
disease and other synucleinopathies. Although usually sporadic, Parkinson’s disease can …
[HTML][HTML] DNA isolation protocol effects on nuclear DNA analysis by microarrays, droplet digital PCR, and whole genome sequencing, and on mitochondrial DNA copy …
E Nacheva, K Mokretar, A Soenmez, AM Pittman… - PLoS …, 2017 - journals.plos.org
… 20 μl of Proteinase K was added to each sample, and digestion was performed at 56C, for 2
… We included 15 μl Proteinase K overnight incubation at 55C as recommended for maximal …
… We included 15 μl Proteinase K overnight incubation at 55C as recommended for maximal …
Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study
…, HJ Clouston, D Travis, K Mokretar… - Blood …, 2023 - ashpublications.org
… Dr Katya Mokretar and Dr Nicola Potter tested the samples prior to issue and reviewed
the manuscript. Dr Andrew Chantry and Mr Liam Whitby reviewed the manuscript. …
the manuscript. Dr Andrew Chantry and Mr Liam Whitby reviewed the manuscript. …
Venetoclax–based low intensity therapy in molecular failure of NPM1-mutated AML
…, J Parker, T Erblich, D Richardson, K Mokretar… - Blood …, 2024 - ashpublications.org
… We did not find 309 differences in responses or outcomes according to K/NRAS or IDH1/2
mutational status in this 310 cohort, although the limited patient numbers preclude any definite …
mutational status in this 310 cohort, although the limited patient numbers preclude any definite …
Association of polymorphisms in endothelial nitric oxide synthesis and renin–angiotensin–aldosterone system with developing of coronary artery disease in bulgarian …
K Mokretar, H Velinov, A Postadzhiyan… - Genetic testing and …, 2016 - liebertpub.com
Aim: The purpose of this study was to evaluate the association of common polymorphisms
in endothelial nitric oxide synthesis (eNOS; G894T) and renin–angiotensin–aldosterone …
in endothelial nitric oxide synthesis (eNOS; G894T) and renin–angiotensin–aldosterone …
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy
Assessment of measurable residual disease (MRD) by quantitative reverse transcription
polymerase chain reaction is strongly prognostic in patients with NPM1-mutated acute myeloid …
polymerase chain reaction is strongly prognostic in patients with NPM1-mutated acute myeloid …
High molecular response rate and overall survival with FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in AML
BackgroundFLT3 inhibitors (FLT3i) represent an important new salvage option in patients
with relapsed FLT3 mutated AML but response rates are low and survival outcomes remain …
with relapsed FLT3 mutated AML but response rates are low and survival outcomes remain …
[HTML][HTML] Investigation of somatic mutations in human brains targeting genes associated with Parkinson's disease
Background: Somatic single nucleotide variant (SNV) mutations occur in neurons but their
role in synucleinopathies is unknown. Aim: We aimed to identify disease-relevant low-level …
role in synucleinopathies is unknown. Aim: We aimed to identify disease-relevant low-level …